A citation-based method for searching scientific literature

Gianluigi Savarese, Javed Butler, Lars H Lund, Deepak L Bhatt, Stefan D Anker. Cardiovasc Res 2021
Times Cited: 2







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
242
100

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
399
100

GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Miriam Longo, Paolo Chiodini, Katherine Esposito. Diabetes Obes Metab 2019
66
100

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
50
50

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
50


A senescent cell bystander effect: senescence-induced senescence.
Glyn Nelson, James Wordsworth, Chunfang Wang, Diana Jurk, Conor Lawless, Carmen Martin-Ruiz, Thomas von Zglinicki. Aging Cell 2012
315
50

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
129
50


A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
744
50

Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
Randa Abdelmasih, Ramy Abdelmaseih, Ravi Thakker, Mohammed Faluk, Arroj Ali, M Mrhaf Alsamman, Syed Mustajab Hasan. Cardiol Res 2021
1
100

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
137
50

Moderate weight loss attenuates chronic endoplasmic reticulum stress and mitochondrial dysfunction in human obesity.
Sandra López-Domènech, Zaida Abad-Jiménez, Francesca Iannantuoni, Aranzazu M de Marañón, Susana Rovira-Llopis, Carlos Morillas, Celia Bañuls, Víctor Manuel Víctor, Milagros Rocha. Mol Metab 2019
17
50


Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
Abba J Kastin, Victoria Akerstrom, Weihong Pan. J Mol Neurosci 2002
332
50

Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
J Decara, P Rivera, S Arrabal, A Vargas, A Serrano, F J Pavón, C Dieguez, R Nogueiras, F Rodríguez de Fonseca, J Suárez. Acta Physiol (Oxf) 2018
24
50

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.
Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takeya. Biochem Biophys Res Commun 2012
87
50


Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
271
50

Accelerated senescence of renal tubular epithelial cells is associated with disease progression of patients with immunoglobulin A (IgA) nephropathy.
Jun Liu, Ju-Rong Yang, Ya-Ni He, Guang-Yan Cai, Jian-Guo Zhang, Li-Rong Lin, Jun Zhan, Jin-Hua Zhang, Hua-Shi Xiao. Transl Res 2012
48
50

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin Pharmacol Ther 2009
269
50

The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Xuping Yang, Qinhui Liu, Yanping Li, Qin Tang, Tong Wu, Lei Chen, Shiyun Pu, Yingnan Zhao, Guorong Zhang, Cuiyuan Huang,[...]. Adipocyte 2020
19
50

Impaired Mitochondrial Biogenesis in Adipose Tissue in Acquired Obesity.
Sini Heinonen, Jana Buzkova, Maheswary Muniandy, Risto Kaksonen, Miina Ollikainen, Khadeeja Ismail, Antti Hakkarainen, Jesse Lundbom, Nina Lundbom, Katriina Vuolteenaho,[...]. Diabetes 2015
148
50

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
266
50


Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Marcel H A Muskiet, Lennart Tonneijck, Yao Huang, Minzhi Liu, Aramesh Saremi, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2018
86
50

Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa. Endocr J 2021
1
100

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging.
Jennifer R Matthews, Lakshini Y Herat, Aaron L Magno, Shelley Gorman, Markus P Schlaich, Vance B Matthews. Biomedicines 2020
3
50

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
202
50

Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Liudmyla G Savchenko, Nataliia I Digtiar, Liudmyla G Selikhova, Elvira I Kaidasheva, Oksana A Shlykova, Liudmyla E Vesnina, Igor P Kaidashev. Rom J Intern Med 2019
9
50


Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
50



Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations.
Mohamed Hassan Elnaem, Noha O Mansour, Abdulrahman Fata Nahas, Mohamed A Baraka, Ramadan Elkalmi, Ejaz Cheema. Int J Gen Med 2020
2
50

Fas mutation reduces obesity by increasing IL-4 and IL-10 expression and promoting white adipose tissue browning.
Eun Wha Choi, Minjae Lee, Ji Woo Song, Kyeongdae Kim, Jungmin Lee, Jehoon Yang, Seo Hyun Lee, Il Yong Kim, Jae-Hoon Choi, Je Kyung Seong. Sci Rep 2020
5
50

CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.
Satoshi Nishimura, Ichiro Manabe, Mika Nagasaki, Koji Eto, Hiroshi Yamashita, Mitsuru Ohsugi, Makoto Otsu, Kazuo Hara, Kohjiro Ueki, Seiryo Sugiura,[...]. Nat Med 2009
50

Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
Eef Hoeben, Willem De Winter, Martine Neyens, Damayanthi Devineni, An Vermeulen, Adrian Dunne. Clin Pharmacokinet 2016
14
50

Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model.
Pin Chen, Xiaozhi Shi, Xiangjin Xu, Yiyang Lin, Zhulin Shao, Rongdan Wu, Lihong Huang. Diabetes Res Clin Pract 2018
19
50

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
Chen-Hsiu Lin, Li Shao, Yu-Mei Zhang, Yu-Ju Tu, Yuzhen Zhang, Brian Tomlinson, Paul Chan, Zhongmin Liu. Expert Opin Pharmacother 2020
8
50

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
194
50


GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.
Ying Ying, Huazhang Zhu, Zhen Liang, Xiaosong Ma, Shiwei Li. J Mol Endocrinol 2015
44
50


Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Mehul Desai, Wayne Shaw, Gordon Law, Marc K Walton, Norm Rosenthal,[...]. Diabetes Obes Metab 2017
72
50

Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.
Anita T Layton, Volker Vallon, Aurélie Edwards. Am J Physiol Renal Physiol 2016
67
50

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.
David M Williams, Marc Evans. Diabetes Ther 2020
4
50

Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
Jacob D Brown, Danielle McAnally, Jennifer E Ayala, Melissa A Burmeister, Camilo Morfa, Layton Smith, Julio E Ayala. Am J Physiol Regul Integr Comp Physiol 2018
6
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.